First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
23-Nov-2005 -
Antigenics Inc. announced that the Brain Tumor Research Center at the University of California, San Francisco, has initiated a Phase 1/2 clinical trial of Oncophage® (vitespen; formerly HSPPC-96), Antigenics' investigational patient-specific cancer vaccine, as a treatment for patients with ...
brain tumors
central nervous system
chemotherapy
+11